Novo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophilia A
Key takeaways
- EU approval of FREHEMGO® could give patients a more convenient, low‑bleed‑risk option and boost Novo’s haemophilia business.
- Annualised bleeding rate <1 in phase 3 population
- Zero treated bleeds in a substantial proportion of participants
- FRONTIER 5 showed no new safety signals when switching from emicizumab
What happened
The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of Novo Nordisk’s new haemophilia A drug, FREHEMGO® (denecimig). The recommendation follows the FRONTIER clinical trial programme, which showed denecimig reduces bleeding episodes and offers flexible dosing (monthly, every two weeks, or weekly) via a pre‑filled pen.
Why it matters
Denecimig is the first factor VIIIa mimetic that can be given once a month, every two weeks, or weekly, potentially lowering treatment burden for people with haemophilia A. The trials demonstrated annualised bleeding rates below 1 and many patients had zero treated bleeds, indicating strong bleed protection. A smooth…
Short-term and longer-term
Short-term. In the next few days, watch the EU market for any regulatory updates or pricing announcements that could affect Novo’s shares.
Longer-term. Over the coming months, the approval of FREHEMGO® could strengthen Novo’s long‑term haemophilia pipeline, potentially increasing revenue streams and market share in a niche but growing therapeutic area.